The French NS-PARK/FCRIN network: a 5-year balance sheet
Objective: To describe the achievements of the French NS-PARK/FCRIN network (http://www.parkinson.network/) after 5 years of activity. Background: The French Clinical Research Infrastructure network FCRIN is…Trends in first line therapy for PD in Wales: A 16 year observational study
Objective: To examine the changes in first line therapy of newly diagnosed Parkinson’s patients between 2000 and 2016 in Wales. Background: There have been several…A Multiple Ascending-Dose Study of LY3154207, A Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)
Objective: Evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple oral LY3154207 (LY) doses in healthy subjects (HS) and persons with Parkinson’s disease (PWPD). Background:…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact of opicapone (OPC) on PDQ-39 in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a once-daily COMT…Wearable sensor use and monitoring effect of dopamine replacement therapy on motor parameters in a real life clinical setting
Objective: To explore the usefulness of wearable sensor data to inform treatment decisions in PD. Background: Wearable sensors are becoming increasingly incorporated into clinical care…Systematic review of Mucuna Pruriens as a treatment for Parkinson’s disease
Objective: To conduct a systematic review of the therapeutic evidence for Mucuna Pruriens (MP) in the treatment of Parkinson’s disease (PD). Background: MP or Velvet bean is a…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to gender: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the patients’ and clinicians’ perception of PD symptoms improvement [as assessed by…Effect of Medication Review on Reported Symptoms in Parkinson’s disease Patients
Objective: The objective was to analyse the effect of structured medication reviews (MR) in ambulatory PD patients on patient reported outcome measures (PROMS). Background: Patients…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 34
- Next Page »